Drug Shortage Report for OCTREOTIDE FOR INJECTABLE SUSPENSION
| Report ID | 166975 |
| Drug Identification Number | 02503786 |
| Brand name | OCTREOTIDE FOR INJECTABLE SUSPENSION |
| Common or Proper name | OCTREOTIDE FOR INJ |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | OCTREOTIDE |
| Strength(s) | 30MG |
| Dosage form(s) | POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT |
| Route of administration | INTRAMUSCULAR |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 1 |
| ATC code | H01CB |
| ATC description | HYPOTHALAMIC HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-08-18 |
| Estimated end date | |
| Actual end date | 2024-06-10 |
| Shortage status | Resolved |
| Updated date | 2024-06-13 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2022-08-18 | English | Compare |